Key trials in Huntington’s disease: SAGE-718, pridopidine, PTC518, & ANX005
In this week’s episode, specialists in the Huntington's disease (HD) field discuss the details of major ongoing studies and give an insight into the implications that their research could have for disease modification and quality of life in HD. The novel agents up for discussion this week are: SAGE-718, a first-in-class oral positive allosteric modulator of NMDAR; pridopidine, an oral sigma-1 receptor agonist; PTC518, an oral RNA splicing modifier; and ANX005, an antibody targeting C1q.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.